Clinical trial
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus…
NCT00404157 · Genentech, Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00404157 |
|---|---|
| Title | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g |
| Official title | A Phase III, Extension Study to Evaluate the Safety of Rituximab Retreatment in Subjects With ISN/RPS 2003 Class III or IV Lupus Nephritis Previously Enrolled in Study U2970g |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lupus Nephritis |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 0 |
| First posted | Nov 27, 2006 |
| Last update posted | Apr 12, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: